BCellOne

BCellOne addresses a key problem in cell and gene therapy: the high cost, safety risks, and inefficiencies of traditional viral vectors and standard electroporation methods, which can cause significant cellular damage. The founding team, with expertise in biotechnology, microfluidics, and nanotechnology, developed a low-voltage electroporation system that minimizes damage while maintaining high transfection efficiency. This breakthrough offers a safer, scalable, and more cost-effective alternative for genetic material delivery, accelerating the development of advanced therapies such as CAR-T cell treatments, gene editing, and regenerative medicine solutions, ultimately improving patient outcomes.